- Home
- SRZN
SRZN
Surrozen Inc.
as 08-12-2025 4:00pm EST
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 85.6M | IPO Year: | N/A |
| Target Price: | $38.50 | AVG Volume (30 days): | 12.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.90 - $18.17 | Next Earning Date: | 08-08-2025 |
| Revenue: | $12,621,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -95.21% | Revenue Growth (next year): | N/A |
Latest Surrozen Inc. News
SRZN Breaking Stock News: Dive into SRZN Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
GlobeNewswire
3 months ago
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
4 months ago
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates
GlobeNewswire
5 months ago
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
Simply Wall St.
7 months ago
Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation
GlobeNewswire
9 months ago
Surrozen to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire
9 months ago
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
GlobeNewswire
9 months ago
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis
Compare SRZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRZN Surrozen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.